Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain inhibitory neurons; strongest in t-cells | 0.75 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 3 Parkinson's papers of 546 | 0.82 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 11050
Sealed predictions
- BCL11B in dopamine neurons, braak-0.73 (p 0.026) → +0.20 (p 0.601)receipt 11057
Swarm cases
receipt 11057: BCL11B in dopamine neurons, braak
- power
- full sample -0.27 (p 0.277, n 18), 95% CI -0.65 to +0.22. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.31 (p 0.207, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.34 (p 0.161, n 18). could be the mix.
- skeptic
- leave-one-out range -0.43 to -0.18, sign flips 0; without severely affected donors -0.27 (p 0.277, n 18). fragile.
- cell type
- strongest in OPCs: -0.65 (p 0.0033, n 18) vs -0.27 in dopamine neurons. proposing OPCs.
- axis
- no measure beats "tracks Braak Lewy-body stage" for BCL11B in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up BCL11B · OPCs · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.15 p 0.594 (needs p < 2.0e-4)
Receipts
loading the receipts